Medial EarlySign Achieves Milestone of 30 Studies in Top Journals on AI for Early Cancer Detection

Medial EarlySign Marks a Milestone with 30 Validated Studies

Medial EarlySign (earlysign.com) is making waves in the healthcare sector by announcing the publication of its 30th validated study in prominent scientific journals. This milestone demonstrates the company's dedication to advancing AI-based clinical predictive analytics, particularly in early cancer detection. The latest study, featured in the British Medical Journal Open Gastroenterology, showcases the effectiveness of Medial EarlySign's ColonFlag™ algorithm in identifying colorectal cancer (CRC) and high-risk adenomas (HRA).

Authored by experts Dr. Ruth M. Ayling and Dr. Finbarr Cotter from Barts and the London School of Medicine, the study highlights ColonFlag's role in significantly enhancing the detection of CRC. It indicates that those with low faecal immunochemical test (FIT) results see improved predictions of colon cancer risk, increasing the chances of cancer findings by 7%.

The study can be accessed through this link, illustrating a commitment to transparency and scientific validation. Since its inception, Medial EarlySign has prioritized independent validation of its technologies across various healthcare settings, partnering with top-tier research institutions to maintain the highest quality standards in clinical applications.

Importance of ColonFlag™ in Clinical Practice

Professor Finbarr Cotter noted, "ColonFlag has been shown to improve prediction of high risk of colon cancer for patients with a low FIT result. We believe that physicians and caregivers can greatly benefit from innovative new technologies that promote engagement and screening, thus providing patients with more precise, personalized care."

Medial EarlySign's commitment to rigorous research extends to the development of its commercial products, which adhere to ISO-compliant standards to ensure reliability and efficacy in clinical environments. This is essential in the healthcare industry, where trust in analytics and predictive tools is paramount.

Ori Geva, Co-founder and CEO of Medial EarlySign, states, "With a foundation built on quality and clinical rigor, we continuously validate our models to demonstrate accurate and effective results across diverse datasets. Our predictive platform aims to assist health systems globally by transforming readily available health data into actionable insights, promoting early detection and healthier outcomes."

The Future of AI in Healthcare

Medial EarlySign offers its tools like the ColonFlag algorithm in the U.S. under the name LGI-Flag™, which helps in detecting lower gastrointestinal disorders. With a focus on harnessing vast datasets, the company aims to optimize diagnostics, enhance medication management, and improve patient outcomes while ensuring that its models are based on peer-reviewed studies recognized by leading healthcare organizations worldwide.

The company's achievements include being named a winner of the CMS AI Health Outcomes Challenge, reflecting its ongoing commitment to improving healthcare through technology.

As Medial EarlySign continues to lead the way in AI-driven healthcare solutions, the focus remains on empowering all stakeholders to keep patients healthier for longer. For more details about their innovative approaches and products, visit earlysign.com.